Monitor for any future conversion to a 13D filing if Acorn's investment approach shifts, or for further stake reductions below the 5% threshold. The passive nature of this filing suggests no imminent activist engagement.
Price Chart
Executive Summary
Acorn Bioventures L.P. and related entities filed an amended Schedule 13G disclosing an aggregate beneficial ownership of 1,284,221 shares (5.7%) of Karyopharm Therapeutics as of September 22, 2026. The filing is a routine passive stake update with no change in investment intent, and the stake appears to have decreased from prior filings, though exact prior figures are not provided in the document.
Key Financial Metrics
Key Facts
- Acorn Bioventures L.P. and related entities collectively own 1,284,221 shares of Karyopharm Therapeutics common stock.
- Aggregate ownership represents 5.7% of shares outstanding based on 22,681,460 shares outstanding as of June 30, 2026.
- Acorn Bioventures L.P. holds 539,373 shares (2.4%) and Acorn Bioventures 2, L.P. holds 744,848 shares (3.3%).
- Filing is a passive investment under Rule 13d-1(c); no control intent is claimed.
- Date of event: September 22, 2026.
Financial Impact
No financial figures disclosed beyond share counts and ownership percentages.
Risk Factors
- Potential further stake reduction by Acorn entities could signal waning institutional confidence.
- Passive filing status limits the likelihood of near-term catalyst from this holder.
Investment Themes
Documents Analyzed
This report is based on 3 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| SC 13G/A Filing (Primary) | 0001636587-26-000084 |
| Document: 0001636587-26-000084-index.html | 0001636587-26-000084 |
| Document: 0001636587-26-000084.txt | 0001636587-26-000084 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 22, 2026 5d ago | 8-K | $0.5175 | awaiting T+60 | — | $0.4800 (+7.25%) |
Oct 14, 2026 13d ago | 8-K | $0.3150 | awaiting T+60 | — | $0.4800 (+52.38%) |
Oct 8, 2026 19d ago | SC 13G/A | $0.6000 | awaiting T+60 | — | $0.4800 (+20.00%) |
Sep 25, 2026 4w ago | SC 13G/A | $1.62 | awaiting T+60 | — | $0.4800 (−70.37%) |
Sep 25, 2026 4w ago | SC 13G/A | $1.62 | awaiting T+60 | — | $0.4800 (−70.37%) |
Sep 11, 2026 6w ago | 8-K | $1.61 | awaiting T+60 | — | $0.4800 (+70.19%) |
Aug 31, 2026 8w ago | 8-K | $2.06 | awaiting T+60 | — | $0.4800 (−76.70%) |
Aug 13, 2026 10w ago | 8-K | $1.99 | awaiting T+60 | — | $0.4800 (+75.88%) |
Aug 10, 2026 11w ago | Press Release | $1.96 | awaiting T+60 | — | $0.4800 (−75.51%) |
Jul 31, 2026 12w ago | 8-K | $1.92 $0.4821 | ▼ −74.89% | ▼ −77.35% | $0.4800 (−75.00%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers